Tumor transition zone: A putative new morphological and functional hallmark of tumor aggressiveness

Oncology Research

Volumn 15, Issue 3, 2005, Pages 169-182

  Bustuoabad, Oscar D ^a   Ruggiero, Raúl A ^a   Di Gianni, Pedro ^a   Lombardi, M Gabriela ^a   Belli, Carolina ^a   Camerano, Gabriela V ^a   Dran, Graciela ^a   Schere Levy, Carolina ^a   Costa, Héctor ^a   Isturiz, Martín A ^a   Narvaitz, Marina ^a   Van Rooijen, Nico ^c   Bustuoabad, Victoria De Los A ^a   Meiss, Roberto P ^b  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Inflammation; Tumor aggressiveness; Tumor transition zone; Vascularization

Indexed keywords

3 METHYLCHOLANTHRENE; CLODRONIC ACID; ETANERCEPT; MEDROXYPROGESTERONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FIBROSARCOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LUNG ADENOCARCINOMA; MALE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; T CELL LYMPHOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR VASCULARIZATION;

EID: 22144438709     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005776367933     Document Type: Article

References (43)

1. Ohori, M.; Wheeler, T. M.; Scardino, P. T. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 74:104-114; 1994.
2. Sobin, L. H.; Wittekind, C. H. TNM classification of malignant tumors. New York: Wiley-Liss; 1997.
3. Katai, H.; Yoshimura, K.; Maruyama, K.; Sasako, M.; Sano, T. Evaluation of the new International Union Against Cancer and American Joint Committee on Cancer TNM staging of gastric carcinoma. Cancer 88:1796-1800; 2000.
4. Longo, D. L. Oncology and hematology, neoplastic diseases. In: Fauci, A. S., ed. Harrison, principles of internal medicine. New York: McGraw-Hill Inc.; 1998:561-568.
5. Tisdale, M. J. Biology of cachexia. J. Natl. Cancer Inst. 89:1763-1773; 1997.
6. Díaz, R.; Ahn, D.; Lopez-Barcons, L.; Malumbres, M.; Perez de Castro, I.; Lue, J.; Ferrer-Miralles, N.; Mangues, R.; Tsong, J.; García, R.; Pérez-Soler, R.; Pellicer, A. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 62:4514-4518; 2002.
7. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 420:860-867; 2002.
8. Brigati, C.; Noonan, D. M.; Albini, A.; Benelli, R. Tumors and inflammatory infiltrates: Friends or foes? Clin. Exp. Metastasis 19:247-258; 2002.
9. Kolb, E. Current knowledge of characteristics and effects of alpha and beta necrosis factors (cachectins). Z. Gesamte Inn. Med. 46:139-144; 1991.
10. Strassmann, G.; Masui, Y.; Chizzonite, R.; Fong, M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol. 150: 2341-2345; 1993.
11. Billingsley, K. G.; Fraker, D. L.; Strassmann, G.; Loeser, C.; Fliot, H. M.; Alexander, H. R. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3:29-35; 1996.
12. Harris, N. L. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392; 1994.
13. Kordon, E.; Lanari, C.; Molinolo, A. A.; Elizalde, P. V.; Charreau, E. H.; Pasqualini, C. D. Estrogen inhibition of MPA-induced mouse mammary tumor transplants. Int. J. Cancer 49:900-905; 1991.
14. Franco, M.; Bustuoabad, O. D.; di Gianni, P. D.; Goldman, A.; Pasqualini, C. D.; Ruggiero, R. A. A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. Br. J. Cancer 74:178-186; 1996.
15. Attia, M. A.; Weiss, D. W. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res. 26:1787-1800; 1966.
16. Tisdale, M. J. Cancer cachexia. Br. J. Cancer 63:337-342; 1991.
17. Tanaka, Y.; Eda, H.; Tanaka, T.; Udagawa, T.; Ishikawa, T.; Horii, I.; Ishitsuka, H.; Kataoka, T.; Taguchi, T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 50:2290-2295; 1990.
18. Kelly, W. R. Diagnóstico Clínico Veterinario (translation of Veterinary Clinical Diagnosis, 1972). Mexico: Compa̧ía Editorial Continental; 1976:13-14.
19. Cruz-Orive, L.; Weibel, E. R. Recent stereological methods for cell biology: A brief survey. Am. J. Physiol. 258: L148-L156; 1990.
20. Mancini, A.; Rabitti, C.; Conte, G.; Gullota, G.; De Marinis, L. Lymphocytic infiltration in thyroid neoplasms. Preliminary prognostic assessments. Minerva Chir. 48:1283-1288; 1993.
21. Sambroock, J.; Fristch, E. F.; Maniatis, T. Purification of nuclear acids. In: Nolan, C., ed. Molecular cloning: A laboratory manual (3rd ed., E3 Book 3). New York: Cold Spring Harbor University Press; 1989.
22. Belli, C.; De Brasi, C.; Larripa, I. Rapid detection of exon 1 NRAS gene mutations using universal heteroduplex generator technology. Hum. Mutat. 21:132-137; 2003.
23. Wang, A. M.; Creasey, A. A.; Ladner, M. B.; Lin, L. S.; Strickler, J.; Van Arsdell, J. N.; Yamamoto, R.; Mark, D. F. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149-154; 1985.
24. Mohler, K. M.; Torrance, D. S.; Smith, C. A.; Goodwin, R. G.; Stremler, K. E.; Fung, V. P.; Madani, H.; Widmer, M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561; 1993.
25. Van Rooijen, N.; Sanders, A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174:83-93; 1994.
26. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194:23-28; 1976.
27. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285:1182-1186; 1971.
28. Rak, J.; Filmus, J.; Kerbel, R. S. Reciprocal paracrine interaction between tumor cells and endothelial cells: The "angiogenesis progression" hypothesis. Eur. J. Cancer 32A:2438-2450; 1996.
29. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407:249-257; 2000.
30. Pluda, J. M. Tumor-associated angiogenesis: Mechanisms, clinical implications and therapeutic strategies. Semin. Oncol. 24:203-218; 1997.
31. O'Byrne, K. J.; Dalgleish, A. G.; Browning, M. J.; Steward, W. P.; Harris, A. L. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer 36: 151-169; 2000.
32. Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am. J. Med. Sci. 105:447-451; 1893.
33. Sirica, A. E. Chronology of significant events in the study of neoplasia. In: Sirica, A. E., ed. The pathobiology of neoplasia. New York: Plenum Press; 1989:1-24.
34. Mandard, A. M.; Petiot, J. F.; Marnay, J.; Mandard, J. C.; Chasle, J.; de Ranieri, E.; Dupin, P.; Berlin, P.; de Ranieri, J.; Tanguy, A.; Boulier, N.; Abbatucci, J. S. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 63:1437-1451; 1989.
35. Dang, L. H.; Bettegowda, Ch.; Huso, D. L.; Kenneth, W.; Kinzler, K. W.; Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 98:15155-15160; 2000.
36. Dvorak, H. F. Tumors: Wounds that do not heal. N. Engl. J. Med. 315:1650-1659; 1986.
37. Lee, A. H. S.; Happerfield, L. C.; Bobrow, L. G.; Millis, R. R. Angiogenesis and inflammation in invasive carcinoma of the breast. J. Clin. Pathol. 50:669-673; 1997.
38. Forsythe, J. A.; Jiang, B. H.; Iyer, N. V.; Agani, F.; Leung, S. W.; Koos, R. D.; Semenza, G. L. Activation of vascular endothelial growth-factor gene-transcription by hypoxia-inducible factor-1. Mol. Cell. Biol. 16:4604-4613; 1996.
39. Leek, R. D.; Landers, R. J.; Harris, A. L.; Lewis, C. E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79:991-995; 1999.
40. Habeck, M. Wielding more power over angiogenesis. Mol. Med. Today 6:138-139; 2000.
41. Schwartsburd, P. M. Chronic inflammation as inductor of pro-cancer microenvironment: Pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 22:95-102; 2003.
42. Weiss, S. J. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365-376; 1989.
43. Shanley, T. P.; Warner, R. L.; Ward, P. A. The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol. Med. Today 1:40-45; 1995.